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Abstract Dose selection for ‘‘ﬁrst in children’’ trials
often relies on scaling of the pharmacokinetics from adults
to children. Commonly used approaches are physiologi-
cally-based pharmacokinetic modeling (PBPK) and allo-
metric scaling (AS) in combination with maturation of
clearance for early life. In this investigation, a comparison
of the two approaches was performed to provide insight
into the physiological meaning of AS maturation functions
and their interchangeability. The analysis focused on the
AS maturation functions established using paracetamol and
morphine paediatric data after intravenous administration.
First, the estimated AS maturation functions were com-
pared with the maturation functions of the liver enzymes as
used in the PBPK models. Second, absolute clearance
predictions using AS in combination with maturation
functions were compared to PBPK predictions for hypo-
thetical drugs with different pharmacokinetic properties.
The results of this investigation showed that AS maturation
functions do not solely represent ontogeny of enzyme
activity, but aggregate multiple pharmacokinetic proper-
ties, as for example extraction ratio and lipophilicity (log
P). Especially in children younger than 1 year, predictions
using AS in combination with maturation functions and
PBPK were not interchangeable. This highlights the
necessity of investigating methodological uncertainty to
allow a proper estimation of the ‘‘ﬁrst dose in children’’
and assessment of its risk and beneﬁts.
Keywords Allometric scaling   Physiologically-based
pharmacokinetic models   Pediatrics   Bridging   Scaling  
Extrapolation
Introduction
Dose selection for ‘‘ﬁrst in children’’ trials of new phar-
maceuticals is often based on scaling of data from adults to
children. The type of data that should be scaled is depen-
dent on the indication, disease process, and outcome of the
therapy in children when compared to adults [1]. In most of
the cases, scaling of the pharmacokinetic data from adults
to children is desirable to either deﬁne the efﬁcacious dose
or for safety purposes to predict the range of drug exposure
after administration of the selected dose(s). Risks associ-
ated with lack of efﬁcacy or safety should be evaluated for
every age category investigated and should ensure there is
a sufﬁcient safety margin across the predicted range of
exposures.
Commonly used approaches for predicting exposures
from adults to children are physiologically-based pharma-
cokinetic modeling (PBPK) and allometric scaling (AS) in
combination with maturation of clearance for early life.
PBPK models are system-speciﬁc models representing the
physiology of the human body by means of mathematical
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physiological blood ﬂows, organ volumes, and partitioning
between blood and organs. When scaling from adults to
children using PBPK, acknowledged differences in all
anatomical and physiological parameters are considered,
being ontogeny on speciﬁc intrinsic clearances normalized
to dry tissue weight of the eliminating organ [2–4].
Thereby variation in plasma concentration–time curves can
in principle be predicted at various ages. Such predictions
can be performed using commercially available software
such as GastroPlus
, PKSim
 and SimCyp
. On the other
hand, AS is a simpliﬁed scaling approach which allows
prediction of volume of distribution and clearance using a
power function for which the exponent is derived based on
theoretical grounds linked to physiology [5]. Accordingly,
total systemic clearance can be predicted by basically
considering a 0.75-exponential relationship with weight.
Besides growth, the gradual development of clearance
pathways can be described with one single maturation
function [6] which is established based on the large amount
of pharmacokinetic data in children across a wide age-
range, necessarily including very young ages [7].
Currently, AS maturation functions are often assumed to
solely represent the ontogeny of the liver enzyme activity
[8] and their use in the scaling of the maturation of other
drugs implicitly assumes interchangeability with other
approaches, as for example PBPK. In this investigation,
this concept was challenged by evaluating the inter-
changeability of PBPK and AS in combination with mat-
uration functions. To this end, this investigation provides
information on the methodological uncertainty of clearance
predictions, which can have a major inﬂuence on the
estimation of the ‘‘ﬁrst dose in children’’ and consequently
on its risk beneﬁt ratio. In addition, we aimed to provide
insights into the physiological meaning of the AS matu-
ration functions for which PBPK deemed suitable as it
separately accounts for different physiological process
including maturation of enzyme activity. A better under-
standing of the AS maturation functions can add in
reducing the methodological uncertainty in future estima-
tions of the ‘‘ﬁrst dose in children’’.
This investigation focused on the AS maturation func-
tions for paracetamol [9] and morphine [10]. Paracetamol
is mainly eliminated by glucuronidation (UGT1A6) and to
a lesser extent by sulfation [11], while morphine is mainly
metabolized by glucuronidation (UGT2B7) [12]. In addi-
tion, differences in the extraction ratio of paracetamol and
morphine allowed investigation into its impact on the
physiological meaning of the AS maturation function.
Next, in order to evaluate the mechanisms affecting the
interchangeability, hypothetical drugs with different phar-
macokinetic properties and elimination via similar meta-
bolic routes were used.
Methods
Morphine and paracetamol
PBPK models for morphine and paracetamol published
earlier by Edginton et al. [2] and Willmann et al. [13] were
used to simulate the expected population pharmacokinetics
in children taking into account inter-individual variability.
Morphine and paracetamol pharmacokinetics in 29 age
groups (0, 3, 7 and 14 days; 1, 2, 3, 6, 9 months; 1, 1.5, and
2 to 18 years in incremental steps of 1 year) were simu-
lated 200 times each. Pre-term neonates were not included
in the simulations. In the simulations a dose of 10 mg
morphine or 1,000 mg paracetamol was intravenously
administered with an infusion time of 1 h. Simulated
concentrations over a 24 h period were sufﬁciently long to
ensure adequate clearance calculations in all age groups
based on the non-compartmental AUC approach. From
these individual simulations, quantiles were calculated and
compared with the quantiles calculated from the simula-
tions using the population pharmacokinetic models. The
latter simulations were based on reported variances and
log-normal distribution. In both simulations, the same set
of demographics was used and correlation between
demographics was accounted for. Demographics were
compiled from the International Commission on Radio-
logical Protection (ICRP) publication [14].
Clearance predictions using PBPK were then compared
to clearance values obtained on basis of published popu-
lation pharmacokinetic models, which were used to
establish the AS maturation functions for paracetamol and
morphine [9, 10].The paracetamol data set included chil-
dren from 37 weeks to 14 years and the morphine dataset
included children from 0 to 3 years, including pre-term and
term neonates. For morphine both the model published by
Bouwmeester et al. [15] and the descriptive model pub-
lished by Knibbe et al. [16] were used for the comparisons.
Both models were developed using the same data set in
children from term-neonates to 3 years old, but the model
published by Knibbe et al. [16] also included pre-term
neonates. The AS maturation functions were graphically
compared with the maturation functions for the enzyme
activities and renal function as applied in the PBPK
models.
Simulations on hypothetical drugs
In total 108 hypothetical drugs were created with different
pharmacokinetic properties being metabolized by either
UGT2B7 (100%) or by a combination of UGT1A6 (65%)
and sulfation (35%) as speciﬁed in Table 1. The physico-
chemical and pharmacokinetic properties were pre-selected
based on factors known to impact the extraction ratio of a
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123compound. These properties were: lipophilicity (log P),
percent relationship between clearance and liver blood
ﬂow, percent of maximum diffusion of the drug into the
liver, and plasma protein binding. In order to reach pre-
deﬁned target values for these properties molecular weight
and intrinsic clearance were adapted. All hypothetical
drugs were assumed to bind to albumin. Hypothetical drugs
with molecular weight greater than 1,000 Da and smaller
than 90 Da were excluded from the analysis to assure that
the created drugs were realistic small molecules.
The remaining hypothetical drugs were used to predict
the clearance in children using both PBPK and AS in
combination with maturation function. In all PBPK simu-
lations 1 mg of the hypothetical drug was administered by
an intravenous infusion of 30 min. Simulated concentra-
tion–time proﬁles were sufﬁciently long to assure adequate
clearance calculation. When AS in combination with
maturation function was used for predictions, Eq. 1 was
applied:
CLchildren ¼ CLadults  
Weightchildren
Weightadults
 0:75
 AS maturation
ð1Þ
where CL adults is the typical value estimated for the adult
population established using PBPK and AS maturation is
the maturation function used in combination with AS. The
AS maturation function is an Emax function, monotonically
increasing from neonates to adults and varying between 0
and 1. Weight in adults was ﬁxed to 70 kg and weight in
children was used as a size parameter and its distribution
was the same as used for the PBPK simulations. The AS
maturation function used was dependent on the metabolic
route of the hypothetical drugs, i.e. for the hypothetical
drugs metabolized by UGT2B7, the AS maturation
function established for morphine was used [10], while
for the hypothetical drugs metabolized by UGT1A6/
Sulfation, the AS maturation function established for
paracetamol was used [9] (Eq. 2).
MFparacetamol ¼
PMA3:92
PMA3:92   54:2
MFmorphine ¼ 1   0:885   exp
 ðPCA   27Þ lnð2Þ
26:6

ð2Þ
where MF is maturation function, PMA is the post-men-
strual age in weeks and PCA is post-conception age weeks.
Graphical analysis
Graphical analyses were performed by assessing absolute
clearance values or the ratio of the estimated clearances
using AS in combination with the maturation function to
T
a
b
l
e
1
O
v
e
r
v
i
e
w
o
f
t
h
e
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
p
r
o
p
e
r
t
i
e
s
o
f
a
l
l
t
h
e
h
y
p
o
t
h
e
t
i
c
a
l
d
r
u
g
s
,
p
a
r
a
c
e
t
a
m
o
l
a
n
d
m
o
r
p
h
i
n
e
D
r
u
g
M
e
t
a
b
o
l
i
c
r
o
u
t
e
a
L
i
p
o
p
h
i
l
i
c
i
t
y
(
l
o
g
P
)
a
C
L
b
l
o
o
d
ﬂ
o
w
(
%
)
a
M
a
x
.
C
L
l
i
v
e
r
d
i
f
f
u
s
i
o
n
(
%
)
a
F
r
e
e
f
r
a
c
t
i
o
n
a
I
n
t
r
i
n
s
i
c
c
l
e
a
r
a
n
c
e
(
L
/
m
i
n
)
b
M
o
l
e
c
u
l
a
r
w
e
i
g
h
t
(
g
/
m
o
L
)
b
E
x
t
r
a
c
t
i
o
n
r
a
t
i
o
c
N
P
a
r
a
c
e
t
a
m
o
l
U
G
T
1
A
6
(
5
8
%
)
0
.
4
6
2
1
0
0
.
8
2
0
.
4
5
5
1
5
1
.
2
0
.
2
7
S
u
l
f
a
t
i
o
n
(
2
9
%
)
C
Y
P
2
E
1
(
1
0
%
)
R
e
n
a
l
(
3
%
)
H
y
p
o
t
h
e
t
i
c
a
l
s
U
G
T
1
A
6
(
6
5
%
)
0
.
4
6
1
0
,
5
0
,
9
0
1
0
,
5
0
,
9
0
0
.
0
5
,
0
.
5
0
,
0
.
9
5
0
.
1
7
–
1
6
4
9
6
–
8
6
5
0
.
0
0
5
6
–
0
.
9
1
1
7
S
u
l
f
a
t
i
o
n
(
3
5
%
)
1
1
0
,
5
0
,
9
0
1
0
,
5
0
,
9
0
0
.
0
5
,
0
.
5
0
,
0
.
9
5
0
.
1
7
–
1
6
4
1
8
5
–
6
0
0
0
.
0
1
7
–
0
.
8
9
1
4
2
5
0
,
9
0
1
0
0
.
0
5
,
0
.
5
0
,
0
.
9
5
2
.
4
0
–
1
7
1
3
7
0
–
6
6
7
0
.
0
7
4
–
0
.
7
2
6
M
o
r
p
h
i
n
e
U
G
T
2
B
7
(
9
0
.
5
%
)
0
.
8
9
9
6
7
8
0
.
7
5
8
9
.
4
2
8
5
.
3
0
.
5
1
C
Y
P
3
A
4
(
5
%
)
R
e
n
a
l
(
4
.
5
%
)
H
y
p
o
t
h
e
t
i
c
a
l
s
U
G
T
2
B
7
0
.
8
9
1
0
,
5
0
,
9
0
1
0
,
5
0
,
9
0
0
.
0
5
,
0
.
5
0
,
0
.
9
5
0
.
1
7
–
1
6
4
1
4
4
–
4
4
6
0
.
0
5
5
–
0
.
9
0
1
5
a
P
r
e
-
d
e
ﬁ
n
e
d
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
p
r
o
p
e
r
t
i
e
s
b
P
a
r
a
m
e
t
e
r
s
a
d
a
p
t
e
d
i
n
t
h
e
m
o
d
e
l
c
R
e
s
u
l
t
a
n
t
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
p
r
o
p
e
r
t
y
J Pharmacokinet Pharmacodyn (2012) 39:195–203 197
123the predicted clearances using PBPK versus age. Com-
parison of inter-individual variability was performed using
a relative prediction interval calculated for every simulated
age group according to Eq. (3)
Relative prediction intervalupper
¼
95thPercentileCL   50thPercentileCL
50thPercentileCL
Relative prediction intervallower
¼
5thPercentileCL   50thPercentileCL
50thPercentileCL
:
ð3Þ
The maturation functions were compared by plotting the
ratio of the AS maturation function to the maturation
function of enzyme activity and renal function as applied in
the PBPK models. These ratios and the ratio of the
clearance predictions using the two scaling approaches
were plotted versus age. In all graphs, the logarithmic scale
of the x axis was used to allow better visualization of the
younger age groups.
Software
PKSim
 version 4.2.4 (Bayer Technology Services GmbH,
Leverkusen, Germany) in combination with RtoMoBi
package version 1.3 (Bayer Technology Services GmbH,
Leverkusen, Germany) was used to generate the models for
the hypothetical drugs [17]. The software database on phys-
iological information and clearance scaling was used to
describe age-dependent differences in organ sizes, tissue
composition (with respect to fat, protein and water content),
blood ﬂow rates, intrinsic clearances, and plasma protein
abundance[2,18,19].Paediatricsimulationswereperformed
using the population wrapper in MoBi
 version 2.3.4 (Bayer
Technology Services GmbH, Leverkusen, Germany). R
version 2.11.1 (R Foundation for Statistical Computing,
Vienna, Austria) was used for AS simulations, including
inter-individual variability, and graphical analysis.
Results
Morphine and paracetamol
Figure 1a and c compares the estimated clearances using
population pharmacokinetic models and predicted clear-
ances using PBPK for paracetamol and morphine versus
age. For paracetamol (a), the clearance predictions using
PBPK were in agreement with the estimated clearances for
the age range of 1–18 years. For morphine (c), the PBPK
predictions of clearance were slightly biased, with clear-
ance being under-predicted in older children ([2.5 months)
and over-predicted in younger children (\2.5 months). The
estimated clearances by Bouwmeester et al. [15] were
consistently higher but following the same pattern as the
PBPK predictions. The relative prediction intervals of
the inter-individual variability as estimated by the popu-
lation pharmacokinetic models and as predicted by PBPK
(Fig. 1b, d) showed that PBPK under-predicts the vari-
ability in all cases. In addition, large differences were
observed in the relative prediction intervals between
the population pharmacokinetic models described by
Bouwmeester et al. [15] and Knibbe et al. [16] which were
developed using the same data set from term neonates to
infants of 3 years old. The simulations of inter-individual
variability based on the model published by Bouwmeester
et al. [15] are likely to be over-estimated as potential
correlations in the omega covariance matrix of random
inter-individual variability could not be considered in the
simulations (not reported in the original publication).
The ratio of estimated clearance using population
pharmacokinetic models to predicted clearance using
PBPK models was evaluated in children from 0 to 18 years
(Fig. 2a, c). Therefore, the estimated clearances and AS
maturation functions had to be extrapolated beyond the age
range investigated in the population pharmacokinetic
models. For morphine, extrapolation of the AS maturation
functions was applied to children older than 3 years and
was considered acceptable as, at this age, maturation is
already at adult levels (Fig. 3d, e). On the contrary, for
paracetamol, extrapolation of the AS maturation function
was also applied to children younger than 37 weeks where
maturation is playing a signiﬁcant role in the prediction of
the total clearance (Fig. 3a–c). In this case, extrapolation
was considered acceptable as it was in close agreement
with the PBPK maturation function of the enzyme activity
(Fig. 2b).
The calculated clearance ratios were used for direct
comparisons with the ratios of the AS maturation function
established using the population pharmacokinetic models to
the maturation functions of the enzyme activities/renal
function as applied in the PBPK models (Fig. 2). For para-
cetamol,comparisonofbothplotsshowsthattheshapeofthe
curves for the clearance ratio is similar to the shape of the
curves for the maturation function (Fig. 2a, b). For mor-
phine, the shape of the curves was not similar (Fig. 2c, d).
Paracetamol and morphine maturation were also analyzed
for the different metabolic pathways (Fig. 3). For paraceta-
mol,thecomparisonoftheASmaturationfunctionswiththe
maturation functions in PBPK showed close agreement only
when both maturation of UGT1A6 and sulfation in a ratio of
65to35wereconsidered(Fig. 3b).Inclusionofamaturation
function for CYP2E1 and renal clearance did not result in a
better agreement between the AS maturation function and
the maturation function as applied in the PBPK model
(Fig. 3c). Comparisons for morphine did not result in total
198 J Pharmacokinet Pharmacodyn (2012) 39:195–203
123Fig. 1 Comparison of absolute
clearance values (a and c) and
relative prediction intervals of
the inter-individual variability
(b and d) estimated using
population pharmacokinetic
models and predicted using
PBPK models. Solid black lines
and intervals represent the
PBPK predictions and dot-
dashed black lines and intervals
represent the estimates using the
population PK models reported
by Anderson et al. [9]i na and
b and Anand et al. [10]i nc and
d. The dashed black lines and
intervals represent the estimates
using the population PK models
reported by Knibbe et al. [16]
and the dotted black lines and
intervals the estimates using the
population PK models reported
by Bouwmeester et al. [15]
Fig. 2 Ratio of the clearances
estimated using population
pharmacokinetic models to the
clearances predicted using
PBPK models (a and c) and the
ratio of AS maturation functions
to maturation functions of
enzyme activities/renal function
as applied in the PBPK models
(b and d)
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123agreement between AS maturation function and the matu-
ration of UGT2B7 (Fig. 3d). Considering maturation of the
enzymeactivityofCYP3A4andglomerularfunctiondidnot
result in a clear change of the shape of the resultant matu-
ration function (Fig. 3e).
Simulations on hypothetical drugs
In total 52 hypothetical drugs metabolized by either
UGT1A6 and sulfation or UGT2B7 were used to predict
the clearance in children by using AS in combination with
a maturation function and by using PBPK models
(Table 1). Figures 4b–d and 5b show the ratio of clearance
predictions for hypothetical drugs with different pharma-
cokinetic properties and similar metabolic route as para-
cetamol and morphine, respectively. For all hypothetical
drugs considerable differences in the prediction were
mainly observed in children younger than approximately
1 year old. For older children the predictions using AS in
combination with a maturation function and PBPK were in
close agreement.
For hypothetical drugs with similar lipophilicity (log P),
metabolic route and extraction ratio as paracetamol, the
prediction ratios along the various ages (Fig. 4b) were in
close agreement with those observed when the PBPK
predictability was assessed for paracetamol (Fig. 4a). In
addition, the magnitude of the prediction differences
increased by increasing the extraction ratio of the hypo-
thetical drug (Fig. 4b). On the other hand, hypothetical
drugs with a very low extraction ratio (\0.05) showed the
largest differences in the predictions (Fig. 4b). For hypo-
thetical drugs with increased lipophilicity, similar meta-
bolic route and similar extraction ratio as paracetamol
(Fig. 4c, d), the prediction ratios between various ages
were seldom comparable to the ones observed when the
PBPK predictability was assessed for paracetamol
(Fig. 4a). In addition, the prediction ratios no longer varied
with the extraction ratio of the hypothetical drugs. Figure 5
shows that hypothetical drugs with similar lipophilicity,
metabolic route and extraction ratio as morphine (b) do not
always have similar prediction ratios as those used to
assess the PBPK predictability for morphine (a).
Discussion
The AS maturation function for clearance pathways in
early life is assumed to solely represent the ontogeny of
Fig. 3 Comparison of the AS maturation functions with the matu-
ration functions of different subset of enzymes activities involved in
the metabolism of paracetamol (a, b and c) and morphine (d and e)a s
applied by the PBPK models. The black dot-dashed lines represent
the AS maturation functions and the black solid lines represent the
maturation function as applied in the PBPK models. In a, the black
solid line represents the enzyme activities of UGT1A6 only; in b, the
black solid line represents the combined enzyme activity of UGT1A6
and sulfation in a ratio of 65 to 35; in c, the black solid line represents
the combined activity of all enzymes/routes including CYP2E1 and
renal clearance; in d, the black solid line represents the enzyme
activities of UGT2B7 only; and in e, the black solid line represents
the combined activity of all enzymes/routes including CYP3A4 and
renal clearance
200 J Pharmacokinet Pharmacodyn (2012) 39:195–203
123liver enzyme activity when scaling clearance of new
pharmaceuticals entities [6, 8]. This approach is accepted
by the regulatory authorities without the requirement
for additional scaling to assess the uncertainty of the pre-
dictions. To this end, interchangeability with other also
scientiﬁcally accepted approaches, such as PBPK, is
implicitly assumed. In this investigation, we successfully
challenged this assumption by comparing clearance
predictions when using AS in combination with maturation
function and PBPK for different hypothetical drugs. It
should be stressed in this respect that the PBPK approach
separately accounts for drug properties and for ontogeny of
different physiological and anatomical aspects, while the
AS approach account for size changes and adopts a single
maturation function for all compounds with a similar
metabolic route. The characteristics of the PBPK approach
Fig. 4 Ratio of clearance
predictions using AS in
combination with maturation
function to clearance
predictions using PBPK models
(to be used as reference for the
simulations using the
hypothetical drugs). a represents
the ratio of estimated clearance
for paracetamol to predicted
clearance by PBPK. The
remaining represent the ratios
for the hypothetical drugs with
log P equal to 0.46 (b), 1 (c) and
2( d). Each line represents one
hypothetical drug: dot-dashed
black lines represent drugs with
very low extraction ratio
(\0.05); dotted black lines
represent drugs with low
extraction ratio (0.05–0.3); solid
black lines represent drugs with
intermediate extraction ratio
(0.3–0.7); and dashed black
lines represent drugs with high
extraction ratio ([0.7)
Fig. 5 Ratio of clearance predictions using AS in combination with
maturation function to clearance predictions using PBPK models
(corrected for differences in clearances of adult values to allow its use
as a reference for the simulations using the hypothetical drugs).
a represents the ratio of estimated clearance for morphine to predicted
clearance by PBPK. b represents the ratios for the hypothetical drugs
with log P equal to 0.89. Each line represents one hypothetical drug:
dotted black lines represent drugs with low extraction ratio
(0.05–0.3); solid black lines represent drugs with intermediate
extraction ratio (0.3–0.7); and dashed black lines represent drugs
with high extraction ratio ([0.7)
J Pharmacokinet Pharmacodyn (2012) 39:195–203 201
123allowed us also to gain insights into the physiological
meaning of the AS maturation function and thereby chal-
lenge the assumption that it solely represents enzyme
activity.
In the ﬁrst step of this investigation, comparison
between PBPK predictions and population pharmacoki-
netic models describing pediatric clinical data were ulti-
mately meant to challenge the assumption that AS
maturation functions solely represent maturation of liver
enzyme activity. Paracetamol and morphine were used as
paradigm drugs based on the availability of AS maturation
functions and were deemed interesting because of the dif-
ferences in extraction ratio. For paracetamol, PBPK pre-
dicted and estimated clearances were in good agreement
(Fig. 1a), while for morphine, the small differences
observed in young children, were randomly distributed
around the PBPK predictions (Fig. 1c). The differences in
estimated clearance could be caused by study differences in
the data used for model development and/or structure of the
model applied [10, 15, 16]. Comparison between PBPK
predicted and estimated inter-individual variability of
clearance indicates that PBPK under-predicts the inter-
individual variability (Fig. 1b, d). Potential under-predic-
tion of inter-individual variability is most likely to be
caused by the fact that variability in the anatomical and
physiological parameters has not yet been well established.
On the other hand, increased inter-individual variability
estimated by population pharmacokinetic models of mor-
phine developed by Anand et al. and Bouwmeester et al.
suggests that ﬁxing AS exponents into the model may
result in an over-estimation of the inter-individual vari-
ability compensating for differences between ‘‘real’’ and
ﬁxed exponent. None of these results should not be inter-
preted to suggest that one approach can be preferred above
the other, but to provide a basis for a better understanding
of the AS maturation function.
For this reason, clearances and maturation functions for
paracetamol and morphine were then compared with PBPK
clearance prediction and maturation function in children
from term neonates to 18 years. For paracetamol, a similar
pattern was observed for the ratio of clearances and mat-
uration functions, suggesting that the AS maturation
function fully represents the PBPK maturation of the
enzyme activity (Fig. 2a, b). On the other hand, lack of
similarity observed for morphine (i.e., patterns show dif-
ferent directions and magnitude) indicates that AS matu-
ration function represents more than only the maturation of
the enzyme activity (Fig. 2c, d). This could be explained
by differences in extraction ratio between paracetamol and
morphine. Paracetamol is a low extraction ratio drug for
which ontogeny of enzyme activity plays a main role in the
maturation of the total clearance, while morphine is an
intermediate extraction ratio drug for which ontogeny of
multiple physiological process such as for example liver
blood ﬂow are also expected to play a role in the matura-
tion of the total clearance [20]. In addition, AS maturation
function for morphine potentially comprises ontogeny of
active processes determining the pharmacokinetics of
morphine [21]. Furthermore, this ﬁrst part of the investi-
gation suggested that paracetamol is primarily metabolized
by UGT1A6 and sulfation (65/35%) (Fig. 3a–c) and mor-
phine mainly by UGT2B7 (Fig. 3d, e), being in agreement
with the literature [11, 12].
In the second step of the investigation, it was examined
to what extent the ﬁndings for paracetamol and morphine
would also apply to hypothetical drugs sharing solely the
same metabolic route. In other words, it was evaluated for
which hypothetical drugs the clearance ratio predicted
using PBPK and AS in combination with maturation
function showed a similar pattern as observed for para-
cetamol and morphine. One could interpret this step of the
investigation as a kind of sensitivity analysis that evaluates
the impact of changes in compound properties on the
prediction ratio of the total clearance in children. Hence,
hypothetical drugs were created assuming similar meta-
bolic routes as for paracetamol and morphine but with
different pharmacokinetic properties pre-selected to lead to
different extraction ratios (Table 1). The hypothetical
drugs were used to predict the clearance in children by
means of PBPK and AS in combination with maturation
function.
For all hypothetical drugs, the clearance predictions
using PBPK and AS in combination with maturation
function provided nearly identical results in children older
than 1 year, which is in agreement with previous ﬁndings
[19]. However, interchangeability in children younger than
1 year for hypothetical drugs having similar metabolic
routes as paracetamol was only observed for drugs with
similar extraction ratio and lipophilicity (log P) (Fig. 4).
These compounds differed from paracetamol only in
intrinsic clearance. From a mechanistic point of view, the
extraction ratio and lipophilicity determine the amount of
drug that is available in the liver for metabolism. Inter-
estingly, for the hypothetical drugs sharing similar meta-
bolic route as morphine, considering extraction ratio and
lipophilicity were shown not to be sufﬁcient to guarantee
the same pattern in clearance prediction ratio as observed
for morphine in children younger than 1 year (Fig. 5). This
could be attributed to the fact that the ontogeny of trans-
porters was not considered in the PBPK simulations while
it was likely to be part of the maturation function used in
the AS simulations [21].
Altogether, these ﬁndings show that interchangeability
in clearance predictions using PBPK and AS in combina-
tion with maturation function cannot be assumed in chil-
dren younger than 1 year for the metabolic routes
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123investigated. Not surprisingly, as at young ages, the
simultaneous ontogeny of multiple physiological processes
is likely to inﬂuence the total clearance of a drug [20]. Also
for this reason, estimation of one single AS maturation
function probably aggregates ontogeny of not only enzyme
activity but of other physiological process. Therefore,
extrapolation of AS maturation function between com-
pounds is most likely only acceptable in very speciﬁc cir-
cumstances, thereby restricting its use for scaling from
adults to children and consequently restricting its applica-
bility in paediatric drug development.
In conclusion, this investigation provided insight into
the physiological meaning of the AS maturation functions.
Moreover, it showed that it is incorrect to assume that
PBPK and AS in combination with maturation function
will always be interchangeable. For this reason, methodo-
logical uncertainty should be considered on a case-by-case
basis when estimating the ‘‘ﬁrst dose in children’’ and
assessing its risk and beneﬁts. In order to reduce this
methodological uncertainty the obtained insights on the
physiological meaning of the AS maturation function
should be acknowledged in future scaling. Further, exten-
sive validation of different prediction approaches using
pediatric clinical data is required to allow improvement of
the predictability and enhance assessment of the uncer-
tainties of both approaches.
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